• Discovery and Development of an Anti-CD40 Agonistic Antibody for Cancer Immunotherapy
  • BSI-508, a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy
  • BSI-507, a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy
  • BSI-001, a Novel Anti-HER2 Antibody Exhibiting Potent Synergistic Efficacy with Trastuzumab
  • BSI-082, a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations
  • BSI-060T,a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号
  • Discovery and Development of an Anti-CD40 Agonistic Antibody for Cancer Immunotherapy
  • BSI-508, a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy
  • BSI-507, a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy
  • BSI-001, a Novel Anti-HER2 Antibody Exhibiting Potent Synergistic Efficacy with Trastuzumab
  • BSI-082, a Fully Human Anti-SIRPα Antibody with Both High Specificity and Broad Coverage of SIRPα Variant Populations
  • BSI-060T,a High Affinity, Fully Human Anti-Siglec-15 Antibody as an Alternative Immune Checkpoint Blocker
Biosion’s Mission
To discover and develop innovative biologics through the synergy of great science, cutting edge technologies and superior craftsmanship for patients worldwide
Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA
BD@Biosion.com
1-302-998-5126
Copyright © 2022. Biosion All rights reserved. 苏ICP备2022027163号